Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20230110057096N1
IRCT20230110057096N1
Recruiting
Phase 3

Evaluation of efficacy of Nicorandil on incidence of contrast-induced nephropathy in patients with GFR < 60% and undergoing coronary angiography and percutaneous coronary intervention- A randomized clinical trial

Rasht University of Medical Sciences0 sites264 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionscontrast-induced nephropathy.Nephropathy induced by other drugs, medicaments and biological substancesICD 10- N1

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
contrast-induced nephropathy.
Sponsor
Rasht University of Medical Sciences
Enrollment
264
Status
Recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Rasht University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •Patients with GFR\<60 ml/min that do not undergo dialysis
  • •Patients who are a candidate for non\-emergent CAG or non\-primary PCI and have 24\-hour time for treatment with Nicorandil

Exclusion Criteria

  • •Consuming Metformin, ACEI, ARB, Nicorandil, Nitrocontin, Sildenafil and other phosphodiesterase 5 inhibitors in the last 24 hours
  • •having urinary tract infection(UTI)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
Evaluation of the oral Nicorandil effect on reducing the contrast-inducedcardiac catheterization.
IRCT20210620051631N1Mashhad University of Medical Sciences344
Completed
Phase 2
Efficacy of nicorandil in acute coronary syndromeAcute coronary syndrome.Ischaemic heart disease120_125
IRCT201202189067N1Vice chancellor for research, Kermanshah University of Medical Siences and Health Services252
Recruiting
Phase 2
The effect of nicorandil on arrhythmia
IRCT20181104041555N1Zahedan University of Medical Sciences100
Recruiting
Phase 2
Effect of the drug Nicorandil in Peripheral Vascular DiseaseHealth Condition 1: I739- Peripheral vascular disease, unspecified
CTRI/2022/01/039444All India Institute of Medical Sciences Rishikesh
Completed
Phase 4
Clinical Efficacy and SAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary InterventionST Elevation Myocardial InfarctionPercutaneous Coronary Intervention
NCT04665648Fudan University1,500